Scilex Holding CO

Scilex Holding Company has entered into a stock repurchase agreement with Vivasor Holding Company to sell previously acquired preferred stock for approximately $12 million, with payments structured in tranches through June 2027.

Scilex Holding Company has signed a binding term sheet with iHolding Group LLP for a proposed $100 million investment in newly issued common stock.

Scilex Holding Company has entered into a binding term sheet to purchase 837 Bitcoin for $50 million from Datavault AI Inc., with an initial payment of $30 million.

Scilex Holding Company stockholders elected a director, ratified auditors, and approved an increase in equity incentive plan shares at the 2026 Annual Meeting.

Scilex Holding Company details the distribution of Dream Bowl Meme Coin I tokens as a dividend to eligible equity holders, outlining the process, record date, and payment date.

Scilex Holding Company's subsidiary, ACEA Therapeutics, Inc., has entered into a definitive agreement to sell 100% of ACEA Pharma, Inc. to Phoenix Asia Holdings Limited for $1 billion in newly-issued Phoenix Asia ordinary shares.

Scilex Holding Company reports Q1 2026 financial results, highlighting ongoing liquidity challenges, legal disputes, and strategic business combinations.

Scilex Holding Company reported a significant increase in net losses and negative working capital, raising substantial doubt about its ability to continue as a going concern, while also adopting a new cryptocurrency treasury strategy.

Scilex Holding Company reports significant net losses and declining revenue across its commercial products, raising substantial doubt about its ability to continue as a going concern.

Scilex Holding Company's Q1 2025 revenue decreased due to lower ZTlido sales, while the company continues to manage its debt and explore strategic opportunities.

Scilex Holding Company's Q3 2024 results show a net loss of $4.4 million, with revenue growth offset by increased operating expenses and strategic financial maneuvers.

Scilex Holding Company's Q2 2024 results show revenue growth driven by ZTlido and ELYXYB, but increased operating expenses and losses.

Scilex Holding Company's 10-K filing provides a comprehensive overview of its securities, financial performance, and strategic initiatives, including its foray into cryptocurrency.

Scilex Holding Company files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding executive compensation and corporate governance.

Scilex Holding Company's 10-K filing highlights its focus on non-opioid pain management through commercialized products and pipeline development.

Scilex Holding Company's recent 10-K filing provides a detailed overview of its securities, including common and preferred stock, warrants, and anti-takeover provisions.

Scilex Holding Co. reports a significant stock transfer by SCLX Stock Acquisition JV LLC to Quantum Scan Holdings, Inc.

Scilex Holding Co. has distributed a stock dividend of Semnur Pharmaceuticals, Inc. common stock to its shareholders and holders of warrants and convertible notes.

Scilex Holding Co. reports a Form 4 filing detailing a warrant transaction by Director and Officer Stephen Ma.

Scilex Holding Co. reports insider transactions involving the acquisition and disposition of warrants by Executive Chairman, CEO, and President Henry Ji.

Scilex Holding Co., a 10% owner and director of Datavault AI Inc., reported the sale of over 15.9 million shares of common stock through a pre-arranged trading plan.

Scilex Holding Co, a 10% owner and director of Datavault AI Inc., reported significant sales of common stock totaling over 14.7 million shares across three days in January 2026.

Scilex Holding Company announces its 2026 Annual Meeting of Stockholders to be held virtually on June 24, 2026.

Scilex Holding Company will hold a special meeting on December 11, 2025, to seek stockholder approval for repricing certain underwater stock options and for a potential meeting adjournment.

Scilex Holding Company will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Scilex Holding Company is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Capital Market and increase the stock price.

Scilex Holding Company will hold its 2024 Annual Meeting of Stockholders virtually on April 5, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Scilex Holding Company reports significant net losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, while also outlining a new, untested cryptocurrency treasury strategy.

Scilex Holding Company files an S-1 registration statement for the resale of up to 1.39 million common shares by Tumim Stone Capital, securing a potential $100 million equity financing to bolster its non-opioid pain management portfolio and operations.

SCLX Stock Acquisition JV LLC has filed an amendment to its Schedule 13D, reporting changes in its beneficial ownership of Scilex Holding Company common stock and Series A Preferred Stock.

Scilex Holding Company reports a dividend distribution of Semnur Pharmaceuticals common stock to its shareholders.

Scilex Holding Company has increased its beneficial ownership in Datavault AI Inc. to 37.27% through recent stock purchases.

Scilex Holding Company has increased its beneficial ownership in Datavault AI Inc. to 40.05% through recent stock acquisitions.

Scilex Holding Company updated its Schedule 13D, disclosing a significant increase in its beneficial ownership of Datavault AI Inc. and the pledging of 85.8 million shares as collateral for a $100 million non-recourse loan.

Scilex Holding Company has significantly increased its beneficial ownership in Datavault AI Inc. to 47.99% after purchasing and exercising a Pre-Funded Warrant.

Oramed Pharmaceuticals Inc. has disclosed a 4.9% beneficial ownership stake in Scilex Holding Co., primarily through warrants and convertible notes.

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Co.

Oramed Pharmaceuticals Inc. has disclosed a 9.9% beneficial ownership stake in Scilex Holding Co, primarily through exercisable warrants.

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants, affirming a passive investment intent.

Oramed Pharmaceuticals Inc. has reported a 6.2% beneficial ownership stake in Scilex Holding Company, comprising common stock and exercisable warrants.